1. Mbatani N, Olawaiye AB., Prat J. Uterine sarcomas. Int J Gynaecol Obstet. 2018;143(Suppl.2): 51–58. https://doi.org/10.1002/ijgo.12613
2. Trope CG., Abeler VM., Kristensen GB. Diagnosis and treatment of sarcoma of the uterus. A review. Acta Oncol. 2012;51(6): 694–705. https://doi.org/10.3109/0284186X.2012.689111.
3. Rizzo A, Pantaleo MA, Saponara M, Nannini M. Current status of the adjuvant therapy in uterine sarcoma: A literature review. World J Clin Cases. 2019;7(14): 1753–1763. https://doi.org/10.12998/wjcc.v7.i14.1753
4. Kristen N Ganjoo, Uterine sarcomas. Curr Probl Cancer. 2019;43(4): 283–288. https://doi.org/10.1016/j.currproblcancer.2019.06.001.
5. Wu TI, Chang TC, Hsueh S, Hsu KH, Chou HH, Huang HJ, et al., Prognostic factors and impact of adjuvant chemotherapy for uterine leiomyosarcoma. Gynecol Oncol. 2006;100(1): 166–172. https://doi.org/10.1016/j.ygyno.2005.08.010
6. Kapp DS, Shin JY, Chan JK. Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy, Cancer 2008;112(4): 820–830. https://doi.org/10.1002/cncr.23245
7. Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The Eighth Edition AJCC Cancer staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging, CA Cancer J Clin. 2017; 67(2): 93–99. https://doi.org/10.3322/caac.21388
8. Nipp R, Tramontano AC, Kong CY, Pandharipande P, Dowling EC, Schrag D, et al., Disparities in cancer outcomes across age, sex, and race/ethnicity among patients with pancreatic cancer. Cancer Med. 2018; 7(2):525–535. https://doi.org/10.1002/cam4.1277
9. Doepker MP, Holt SD, Durkin MW, Chu CH, Nottingham JM, Triple-Negative Breast Cancer: A Comparison of Race and Survival, Am Surg. 2018; 84(6): 881–888.
10. Hosh M, Antar S, Nazzal A, Warda M, Gibreel A, Refky B. Uterine sarcoma: analysis of 13,089 cases based on surveillance, epidemiology, and end results database, Int J Gynecol Cancer. 2016;26(6): 1098–104. https:// dx.doi.org/10.1097/IGC.0000000000000720
11. Surveillance Research Program, National Cancer Institute SEER*Stat software (seer.cancer.gov/seerstat) version < SEER*Stat 8.3.6.1>.
12. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Available at http://seer.cancer.gov. 2020; Assessed July 14.
13. Yang J, Li YJ, Liu QQ, Li L, Feng AZ, Wang TY, et al. Brief introduction of medical database and data mining technology in big data era. Journal of Evidence-Based Medicine. 2020; 13(1): 57–69. https://doi.org/10.1111/jebm.12373
14. Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M Obuchowski, N, et al. Assessing the performance of prediction modelsm epidemiology: A Framework for Traditional and Novel Measures. Epidemiology 2010;21(1):128–138. https://doi: 10.1097/EDE.0b013e3181c30fb2
15. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models, Med Decis Making. 2006; 26(6): 565–74. https://doi.org/10.1177/0272989X06295361
16. Grimes DA. The nomogram epidemic: resurgence of a medical relic, Ann Intern Med. 2008;149(4):273-5. DOI: 10.7326/0003-4819-149-4-200808190-00010
17. Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: more than meets the eye, Lancet Oncol. 2015;16(4) : 173–80. https://doi.org/10.1016/S1470-2045(14)71116-7
18. Chen Y, Liao F, Cao L.Web-based nomograms for predicting the prognosis of adolescent and young adult skin melanoma, a large population-based real-world analysis. Transl Cancer Res, 2020;9(11): 7103–7112. https://dx.doi.org/10.21037/tcr-20-1295
19. Zhou JG, Zhao HT, JIN SH, Tian X, Ma H. Identification of a RNA-seq-based signature to improve prognostics for uterine sarcoma, Gynecol Oncol. 2019;155(3): 499-50719. https://doi.org/10.1016/j.ygyno.2019.08.033
20. Li Y, Ren HT, Wang JM. Outcome of adjuvant radiotherapy after total hysterectomy in patients with uterine leiomyosarcoma or carcinosarcoma: a SEER-based study, BMC Cancer. 2019;19(1): 697. https://doi.org/10.1186/s12885-019-5879-7
21. Sait HK, Anfinan NM, Sayed ME. El, AlkhayyatSS, Ghanem AT, Abayazid RM, et al. Uterine sarcoma: Clinico-pathological characteristics and outcome. Saudi Med J. 2014; 35(10): 1215–1222.
22. Brooks SE, Zhan M, Cote T, Baquet CR. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989–1999. Gynecol Oncol. 2004;93(1): 204–208. https://doi.org/10.1016/j.ygyno.2003.12.029
23. Varlotto JM, McKie K, Voland RP, Flickinger JC, DeCamp MM, Maddox D, et al. The role of race and economic characteristics in the presentation and survival of patients with surgically resected non-small cell lung cancer. Front Oncol. 2018;8: 146. https://doi.org/10.3389/fonc.2018.00146.
24. Wu Y, Ai Z, Xu G. Marital status and survival in patients with non-small cell lung cancer: An analysis of 70006 patients in the SEER database. Oncotarget., 2017;8(61) :103518–103534. https://doi.org/10.18632/oncotarget.21568.
25. Goldzweig G, Andritsch E, Hubert A, Brenner B, Walach N, Perry S, et al. Psychological distress among male patients and male spouses: what do oncologists need to know? Ann Oncol., 2010; 21(4): 877–883. https://doi.org/10.1093/annonc/mdp398.
26. Champetier C, Hannoun-Levi JM, Resbeut M, Azria D, Salem N, Tessier E, et al. Postoperative radiotherapy of uterine sarcoma: a multicentric retrospective study. Cancer Radiother. 2011; 15(2): 89–96. https://doi.org/10.1016/j.canrad.2010.05.005.
27. Wong P, Han K, Sykes J, Catton C, Laframboise S, Fyles A, et al. Postoperative radiotherapy improves local control and survival in patients with uterine leiomyosarcoma. Radiat Oncol. 2013;24(8): 128. https://doi.org/10.1186/1748-717X-8-128.
28. Hensley ML, Ishill N, Soslow R, Larkin J, Abu-Rustum N, Sabbatini P, et al. Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study. Gynecol Oncol., 2009; 112(3): 563-7. https://doi.org/10.1016/j.ygyno.2008.11.027
29. Littell RD, Tucker LY, Raine-Bennett T, Palen TE, Zaritsky E, Neugebauer R, et al. Adjuvant gemcitabine-docetaxel chemotherapy for stage I uterine leiomyosarcoma: Trends and survival outcomes, Gynecol Oncol., 2017;147(1): 11–17. https://doi.org/10.1016/j.ygyno.2017.07.122